Compare Advanced Micro Devices (AMD) vs DexCom, Inc. (DXCM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Advanced Micro Devices vs DexCom, Inc. — how do they compare? Advanced Micro Devices trades at $541.58 (market cap $909.70B), while DexCom, Inc. trades at $75 (market cap $28.93B). The key difference: Advanced Micro Devices is far larger — about 31.4× DexCom, Inc.'s market cap, and Advanced Micro Devices is trading nearer its 52-week high, DexCom, Inc. nearer its low. Which is the better fit depends on your goals.
| AMD | DXCM | |
|---|---|---|
Market Cap | $909.70B | $28.93B |
Sector | Technology | Health |
52-Week High | $580.91 | $89.53 |
52-Week Low | $146.24 | $54.84 |
Enterprise Value | $901.22B | $27.89B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMD trades at $557.89, up 2.04% today and near its 52-week high, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth, with 2025 revenue reaching $34.64 billion and net income surging to $4.34 billion, though valuation ratios like P/E of 185.96 indicate premium pricing. Recent earnings beats and positive AI-driven news fuel investor optimism.
Outlook remains positive due to AI demand and earnings momentum, but high valuations and intense competition pose risks. Analyst consensus is strongly bullish with a $508.24 price target, though the stock trades above this, suggesting near-term caution amid long-term growth potential.
DXCM trades at $74.96, up 2.66% today, with strong technical momentum as price approaches resistance near $76. The company demonstrates robust fundamentals with revenue growth from $2.9B in 2022 to $4.7B in 2025 and expanding net margins to 17.93%. Recent FDA clearance for pediatric Stelo CGM and positive CONNECT trial results support growth in the non-insulin diabetes market.
Outlook remains positive with 80% analyst buy ratings and $83.78 consensus target, though risks include GLP-1 drug competition and execution in expanding beyond insulin-dependent patients. Earnings beat expectations in three consecutive quarters, with Q2 2026 results anticipated July 30, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Advanced Micro Devices
Advanced Micro Devices, Inc. (AMD) produces semiconductor products and devices. The Company offers products such as microprocessors, embedded microprocessors, chipsets, graphics, video and multimedia products and supplies it to third-party foundries, as well as provides assembling, testing, and packaging services. AMD serves customers worldwide.
Read more on AMD →About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →
